2-FEA

hypertension, coronary artery disease, cardiomyopathy, arrhythmias, cerebrovascular disease

Pre-existing cardiovascular conditions significantly elevate the risk of acute cardiovascular events when combined with a catecholamine-releasing stimulant. 4-Fluoroamphetamine produces exaggerated blood pressure effects relative to both MDMA and amphetamine in emergency presentations (Gresnigt et al. 2022), and amphetamine-type stimulants broadly cause hypertension, tachycardia, and endothelial dysfunction (Annawald et al. 2024). No substance-specific cardiovascular data exist for 2-FEA; this contraindication is inferred from the amphetamine class and 4-FA analog data.

epilepsy, seizure disorders, history of seizures

Stimulants lower seizure threshold as a class effect. Individuals with epilepsy or other seizure disorders face elevated risk of breakthrough seizures. No 2-FEA-specific seizure data exist; this is a class-level inference from amphetamine pharmacology.

schizophrenia, schizoaffective disorder, psychotic disorders, severe anxiety disorders, bipolar disorder

Amphetamine-class stimulants carry documented risks of precipitating or exacerbating psychosis, panic, and mania. Community reports note anxiety and paranoia at high doses of 2-FEA. No 2-FEA-specific psychiatric outcome data exist; this is inferred from amphetamine class pharmacology and community reports.

hyperthyroidism, thyrotoxicosis

Hyperthyroidism produces a state of elevated sympathetic nervous system activity. Adding a catecholamine-releasing stimulant compounds tachycardia, hypertension, tremor, and hyperthermia risk. This is a standard amphetamine class contraindication.

pregnancy, lactation, breastfeeding

Amphetamine-type stimulants are associated with adverse fetal outcomes including low birth weight, preterm delivery, placental abruption, and neonatal withdrawal. No 2-FEA-specific reproductive data exist; this contraindication is inferred from amphetamine class data.

MAOI antidepressants, reversible MAOIs, MAO-B inhibitors at non-selective doses

Concurrent use of any MAOI with a monoamine releasing agent risks fatal hypertensive crisis and serotonin syndrome. Amphetamine derivatives themselves exhibit MAO inhibitory activity at higher concentrations (Reyes-Parada et al. 2019), compounding the risk. This is a well-established class interaction applying to all amphetamine-type stimulants.

SSRIs, SNRIs, tramadol, other serotonin-active drugs

Serotonergic medications combined with a monoamine releaser that may have SERT activity create conditions for serotonin toxicity syndrome. The severity ranges from relative to absolute depending on the specific agent and dosage. Tramadol is specifically flagged as a lethal interaction in the seed data due to combined SERT/NET inhibition and seizure threshold reduction. SSRIs and SNRIs present pharmacodynamic interaction via additive serotonin load (Inan et al. 2020).